Shinhan Bank in South Korea completed a stablecoin pilot for corporate overseas remittances using the Solana blockchain, allowing clients to make payments without interacting with crypto wallets or tokens. The pilot tested a full payment workflow integrated into the bank's existing systems with privacy protections on a private Solana network. This approach aims to keep stablecoin use invisible to clients while leveraging blockchain efficiency. The next steps depend on South Korea's pending Digital Asset Basic Act, which will shape regulatory approval and commercial rollout. Shinhan Financial is also exploring retail stablecoin payments via its sister company, Shinhan Card, indicating a dual focus on corporate and consumer blockchain solutions.
Shinhan Bank's stablecoin pilot for corporate overseas remittances is the subject, with Pluang market data as context for readers. As of Oct 02, 2026 02:41 WIB, 30 of 50 major cryptocurrencies on Pluang rose while 19 fell. Notable movers include SAND at Rp794 with a 3.50% increase and a Pluang order activity skewed 76% Sell / 24% Buy, COMP at Rp429.188 down 3.45% with 24% Sell / 76% Buy, and SUSHI at Rp4.710 down 3.14% with 70% Sell / 30% Buy. The most notable figure is SAND's 76% sell-side order activity.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
